Jupiter Neurosciences Inc (JUNS)

$JUNS I bet this piece of shit will drop more today !! 🤬

$JUNS how did I end up here?? ✅💚😂

$JUNS wtf. Short more?

$JUNS $UFG I expect to see a return of at least 20% or 30%, or even more, on each soon. Juns needs to regain Nasdaq's performance and will likely do so, just like a year ago. They might surprise us in their next financial report. UFG is doing well; perhaps they could have a surprise announcement soon, but purely speculatively, I think they could return to 1.25 soon.

$JUNS I got robbed on this turd 💩

$JUNS I know several people that are victims of this scam described in this video , this stock $JUNS was one of the multiple stocks that was used for this scam. I fell for it too https://youtu.be/JHdJEYJ6ucY?si=G2Z9LwlzjZRNEH5K

The B2i Digital team is pleased to announce that Jupiter Neurosciences, Inc. (Nasdaq: $JUNS ), a B2i Digital Featured Company, is participating in the Life Sciences Virtual Investor Forum, co-hosted by Virtual Investor Conferences and Zacks Small Cap Research, on Tuesday, March 11, 2026, at 1:30 PM EDT. The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/otc-life-sciences-virtual-investor-forum For the full B2i Digital profile of Jupiter Neurosciences, please visit: https://b2idigital.com/jupiter-neurosciences-1 Virtual Investor Conferences brings together public companies and a global audience of retail and institutional investors for live executive presentations, Q&A sessions, and on-demand replays. The platform is open to public companies listed on NYSE, Nasdaq, TSX, CSE, ASX, and the OTC Markets. Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on developing therapies for neuroinflammation and central nervous system disorders. The company’s lead clinical program is advancing through a Phase IIa trial in Parkinson’s disease. Jupiter is also commercializing Nugevia, a consumer product built on its patented JOTROL technology platform designed to enhance resveratrol bioavailability. Jupiter’s dual-path strategy combines clinical development with commercial revenue generation. Presenting on behalf of Jupiter Neurosciences will be Christer Rosén, Founder, Chairman and Chief Executive Officer. Mr. Rosén brings a track record of building companies across multiple industries. He previously served as Chairman and CEO of EffRx Pharmaceuticals for 17 years, where he guided the company through FDA and EU approvals of Binosto, a treatment for osteoporosis, providing him with extensive experience across pharmaceutical development, regulatory pathways and global distribution. To register for this presentation, visit: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5271529/jupiter-neurosciences-inc-nasdaq-juns?utm_source=b2i&utm_medium=marketing&utm_campaign=0326LifeSciencesVIC For more information about Jupiter Neurosciences, visit: https://jupiterneurosciences.com/investors/ Content about any specific company was provided and approved by that company or is available in the public domain. B2i Digital, Inc. has not independently verified the accuracy of the information contained herein. The content contained herein is informational only, and no content contained herein shall be considered an offer to solicit the sale of any security or make a recommendation to purchase a security. B2i Digital is not a broker-dealer or investment adviser.

$JUNS You really think there is a hope for this piece of shit 💩? 🤣🤣

$JUNS something has changed to cause a +9% jump - hopefully it’s something that was said at the BIO conference

$JUNS Let me guess! This shit will drop another %10 today 🤣🤣🤣🤣

$JUNS Delist this trash 💩

$JUNS Ridiculous piece of shit ! Every day 10% drop Motherfucker ?

$JUNS What’s wrong with this piece of shit ?!!!

$JUNS Shit hole of the stocks ! 💩💩 the mother fucker keeps dipping !

$JUNS Piece of shit 💩

$JUNS Has this piece of shit ever have one Green Day ?!!!

Jupiter Neurosciences, Inc. (NASDAQ: $JUNS), a B2i Digital Featured Company, announced that management will present at the BIO Investment and Growth Summit 2026, hosted by the Biotechnology Innovation Organization (BIO), taking place March 2 to 3, 2026, in Miami Beach, Florida. The Company’s corporate presentation is scheduled for March 2, 2026, at 2:30 PM Eastern. At BIO, Jupiter will discuss its FDA-cleared Phase IIa clinical program in Parkinson’s disease. The U.S. Food and Drug Administration granted the Company’s Investigational New Drug (IND) application in November 2025, authorizing initiation of the trial. The IND clearance followed preclinical data demonstrating a nine-fold improvement in JOTROL™ bioavailability compared to standard resveratrol formulations, and documented translational proof-of-concept in Parkinson’s disease models. “We approach development with discipline and a clear execution plan,” said Christer Rosén, Chairman and Chief Executive Officer. “With our Phase IIa program underway and defined milestones in front of us, we look forward to engaging with investors and potential partners at BIO. At the same time, we continue building revenue and commercial cash flow through Nugevia™.” In addition to advancing its clinical pipeline, Jupiter generates revenue through Nugevia™, a consumer product built on its patented JOTROL™ technology platform. Publicly disclosed e-commerce metrics reflect repeat purchase activity of approximately 25 percent and product return rates of approximately 3 percent. Management believes these metrics demonstrate early commercial validation and support a capital-efficient operating model that differentiates Jupiter from biotechnology peers that rely solely on external financing. Management will be available for scheduled one-on-one meetings throughout the BIO Investment and Growth Summit 2026. Read the full press release: https://jupiterneurosciences.com/press-releases/?i=162897. Learn more about Jupiter Neurosciences at the B2i Digital Featured Companies profile: https://b2idigital.com/jupiter-neurosciences-1 Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison D. Silva, President and CBO; Saleem Elmasri, CPA, CFO; and Marshall Hayward, Ph.D., Co-Founder and CSO. To learn more about the company, visit www.jupiterneurosciences.com. For investor inquiries, contact [email protected]. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.

$JUNS several non compliance notices with Nasdaq requirements have been received

$JUNS Current Stock Price: $0.57

Jupiter Neurosciences, Inc. (NASDAQ: $JUNS ), a B2i Digital Featured Company, has been invited to present its progress at a private investor dinner this evening at The Mar-a-Lago Club in Palm Beach, Florida. Tonight’s event, Wednesday, February 25, 2026, at 6:00 PM ET, is organized by the Money Channel NYC and brings together a select group of accredited and high-net-worth investors to discuss emerging investment opportunities. Jupiter is the only presenting company on tonight’s agenda. Learn more about Jupiter Neurosciences at the B2i Digital Featured Companies profile: https://b2idigital.com/jupiter-neurosciences-1. Senior management is expected to cover updates on the Phase IIa Parkinson’s program, the company’s broader neuroinflammation pipeline, and continued commercial execution of Nugevia™, the Company’s patented JOTROL™-based resveratrol platform. Jupiter’s dual-path strategy combines active clinical development with commercial revenue generation. The company views direct engagement with the investment community as an ongoing part of its philosophy to remain accessible and transparent, and management expects to continue participating in investor meetings and forums over time. Those interested in further information or in arranging future meetings with the Jupiter executive team are encouraged to contact [email protected]. Read the full press release: https://www.pressviewer.com/profiles/investor/NewsPrint.asp?b=3018&ID=162733&m=rl&v=2&g=3007. Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison D. Silva, President and CBO; Saleem Elmasri, CPA, CFO; and Marshall Hayward, Ph.D., Co-Founder and CSO. To learn more about the company, visit www.jupiterneurosciences.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.

Jupiter Neurosciences, Inc. (NASDAQ: $JUNS) today announced that it has entered into an Omnibus Amendment with YA II PN, Ltd., modifying the installment payment provisions of its previously disclosed Convertible Promissory Notes issued under the Company's Standby Equity Purchase Agreement. Under the amendment, monthly installment payments will now begin on April 1, 2026, with principal repayments following a defined schedule agreed between the Company and Yorkville. The core economic terms of the $6.0 million financing remain unchanged. Jupiter Neurosciences is a B2i Digital Featured Company. View the company profile at https://b2idigital.com/jupiter-neurosciences-1. The amendment relates solely to installment timing and application mechanics; it does not alter the underlying economic terms of the financing, nor does it introduce any new pricing provisions, reset features, or additional financing commitments. "This amendment reflects a deliberate and aligned decision between Jupiter and Yorkville," said Christer Rosén, Chairman and Chief Executive Officer of Jupiter Neurosciences. "Yorkville demonstrated its commitment to our long-term strategy by adjusting installment timing without changing pricing, maturity or other economic terms. That alignment enables us to remain focused on advancing our Phase II Parkinson's program while continuing to scale Nugevia™ and build commercial cash flow." In addition to advancing its neuroinflammation pipeline, the Company notes that it is generating revenue through Nugevia™, its patented JOTROL™-based resveratrol platform. Current ecommerce sales reflect repeat purchase activity of approximately 25 percent and product return rates of approximately 3 percent. See the full news release at https://www.pressviewer.com/ViewEmail.asp?b=3018&id=383681&p=2423532&I=1447373-F8U6y4D6y3. Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for neuroinflammation and central nervous system disorders. The Company's lead clinical program is advancing through a Phase IIa trial in Parkinson's disease. Jupiter is also commercializing Nugevia™, a consumer product built on its patented JOTROL™ technology platform designed to enhance resveratrol bioavailability. Jupiter's dual-path strategy combines clinical development with commercial revenue generation. The company is led by Christer Rosén, Founder, Chairman and CEO; Alison D. Silva, President and CBO; Saleem Elmasri, CPA, CFO; and Marshall Hayward, Ph.D., Co-Founder and CSO. Learn more at www.jupiterneurosciences.com. Investor inquiries: [email protected]. Discover more emerging growth Featured Companies and upcoming Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.